The mobile version of the Asarina Pharma website is under construction. For the best experience, please use a desktop when browsing.
REMAIN IN CONTROL OF YOUR LIFE
You may not have heard of ‘Allopregnanolone’, but you could well care for one of the millions who suffer from its effects.
From Tourette syndrome to OCD, PTSD, stress-related fatigue, compulsive gambling, addiction and PMDD—the potent neurosteroid Allopregnanolone is implicated in them all.
Our novel treatment Sepranolone is the endogenous compound that modulates the effects of Allopregnanolone. It has been developed from over 40 years’ neuroendocrinological research.
“I believe Sepranolone will always attract interest from clinicians and patients, whatever indication it is launched for.”Professor Marie Bixo, University of Umeå
The neurochemical GABA is the brain’s most powerful inhibitory neurotransmitter. It plays a crucial role in inhibiting and reducing stress, fear and anxiety levels. But what keeps GABA in check? The neurosteroid Allopregnanolone (or ALLO) is a potent modulator of GABA, acting on the GABA-A receptor, a major pathway for GABA within the brain.
The body’s endogenous compound—Sepranolone—regulates and modulates the negative effects of ALLO. Asarina Pharma is the first company to have developed and synthesized Sepranolone as a medication, patenting a pharmaceutical formulation in 2010.
Sepranolone has achieved an excellent safety profile in substantial clinical trials and is currently being run in a study for Menstrual Migraine. It will be tested in a Tourette syndrome study in 2021.